BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 34078314)

  • 21. Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma.
    Usmani SZ; Cavenagh JD; Belch AR; Hulin C; Basu S; White D; Nooka A; Ervin-Haynes A; Yiu W; Nagarwala Y; Berger A; Pelligra CG; Guo S; Binder G; Gibson CJ; Facon T
    J Med Econ; 2016; 19(3):243-58. PubMed ID: 26517601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials.
    Mateos MV; Oriol A; Martínez-López J; Teruel AI; Bengoechea E; Palomera L; de Arriba F; Esseltine DL; Cakana A; Pei L; van de Velde H; Miguel JS
    Ann Hematol; 2016 Dec; 95(12):2033-2041. PubMed ID: 27738789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First-line Daratumumab in Addition to Chemotherapy for Newly Diagnosed Multiple Myeloma Patients Who are Transplant Ineligible: A Cost-Effectiveness Analysis.
    Li S; Li J; Peng L; Tan C; Zeng X; Peng C; Zhang C; Li Y; Wan X
    Clin Ther; 2021 Jul; 43(7):1253-1264.e5. PubMed ID: 34193346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect
    Abonour R; Rifkin RM; Gasparetto C; Toomey K; Durie BGM; Hardin JW; Terebelo HR; Jagannath S; Narang M; Ailawadhi S; Omel JL; Lee HC; Srinivasan S; Kitali A; Agarwal A; Wagner L;
    Br J Haematol; 2021 Apr; 193(1):93-100. PubMed ID: 33118614
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment.
    Lee SR; Choi H; Lee BH; Kang KW; Yu ES; Kim DS; Park Y; Choi CW; Kim BS; Sung HJ
    Korean J Intern Med; 2019 Nov; 34(6):1333-1346. PubMed ID: 30360024
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma.
    Kim MK; Kim K; Min CK; Kwak JY; Bae SB; Yoon SS; Lee JJ; Kim KH; Nam SH; Mun YC; Kim HJ; Bae SH; Shin HJ; Lee JH; Park JS; Jeong SH; Lee MH; Kim YS; Lee HS; Park KW; Lee WS; Lee SM; Lee JO; Hyun MS; Jo DY; Lim SN; Lee JH; Cho DY; Do YR; Kim JA; Park SK; Kim JS; Kim SJ; Kim H; Yi HG; Moon JH; Choi CW; Kim SH; Joo YD; Kim HG; Kim BS; Park MR; Song MK; Kim SY
    Oncotarget; 2017 Jun; 8(23):37605-37618. PubMed ID: 28402945
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM.
    Mateos MV; Martínez-López J; Hernández MT; Ocio EM; Rosiñol L; Martínez R; Teruel AI; Gutiérrez NC; Martín Ramos ML; Oriol A; Bargay J; Bengoechea E; González Y; Pérez de Oteyza J; Gironella M; Encinas C; Martín J; Cabrera C; Paiva B; Cedena MT; Puig N; Bladé J; Lahuerta JJ; San-Miguel J
    Blood; 2016 Jan; 127(4):420-5. PubMed ID: 26500339
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone.
    Harousseau JL; Palumbo A; Richardson PG; Schlag R; Dimopoulos MA; Shpilberg O; Kropff M; Kentos A; Cavo M; Golenkov A; Komarnicki M; Mateos MV; Esseltine DL; Cakana A; Liu K; Deraedt W; van de Velde H; San Miguel JF
    Blood; 2010 Nov; 116(19):3743-50. PubMed ID: 20628153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma.
    San-Miguel J; Bladé J; Shpilberg O; Grosicki S; Maloisel F; Min CK; Polo Zarzuela M; Robak T; Prasad SV; Tee Goh Y; Laubach J; Spencer A; Mateos MV; Palumbo A; Puchalski T; Reddy M; Uhlar C; Qin X; van de Velde H; Xie H; Orlowski RZ
    Blood; 2014 Jun; 123(26):4136-42. PubMed ID: 24833354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.
    San Miguel JF; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Delforge M; Jiang B; Mateos MV; Anderson KC; Esseltine DL; Liu K; Deraedt W; Cakana A; van de Velde H; Richardson PG
    J Clin Oncol; 2013 Feb; 31(4):448-55. PubMed ID: 23233713
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study.
    Chari A; Rodriguez-Otero P; McCarthy H; Suzuki K; Hungria V; Sureda Balari A; Perrot A; Hulin C; Magen H; Iida S; Maisnar V; Karlin L; Pour L; Parasrampuria DA; Masterson T; Kosh M; Yang S; Delioukina M; Qi M; Carson R; Touzeau C
    Br J Haematol; 2021 Mar; 192(5):869-878. PubMed ID: 33216361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A matching-adjusted indirect treatment comparison (MAIC) of daratumumab-bortezomib-melphalan-prednisone (D-VMP) versus lenalidomide-dexamethasone continuous (Rd continuous), lenalidomide-dexamethasone 18 months (Rd 18), and melphalan-prednisone-thalidomide (MPT).
    Dimopoulos MA; Cavo M; Mateos MV; Facon T; Heeg B; van Beekhuizen S; Gebregergish SB; Nair S; Pisini M; Lam A; Slavcev M
    Leuk Lymphoma; 2020 Mar; 61(3):714-720. PubMed ID: 31686559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma.
    Facon T; Lee JH; Moreau P; Niesvizky R; Dimopoulos M; Hajek R; Pour L; Jurczyszyn A; Qiu L; Klippel Z; Zahlten-Kumeli A; Osman M; Paiva B; San-Miguel J
    Blood; 2019 May; 133(18):1953-1963. PubMed ID: 30819926
    [TBL] [Abstract][Full Text] [Related]  

  • 34. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
    Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
    Palumbo A; Bringhen S; Larocca A; Rossi D; Di Raimondo F; Magarotto V; Patriarca F; Levi A; Benevolo G; Vincelli ID; Grasso M; Franceschini L; Gottardi D; Zambello R; Montefusco V; Falcone AP; Omedé P; Marasca R; Morabito F; Mina R; Guglielmelli T; Nozzoli C; Passera R; Gaidano G; Offidani M; Ria R; Petrucci MT; Musto P; Boccadoro M; Cavo M
    J Clin Oncol; 2014 Mar; 32(7):634-40. PubMed ID: 24449241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma.
    Zeng X; Liu Q; Peng L; Peng Y; Yi L; Luo X; Li S; Wan X; Tan C
    Adv Ther; 2021 May; 38(5):2379-2390. PubMed ID: 33770365
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Continuous lenalidomide treatment after bortezomib-melphalan-prednisolone therapy for newly diagnosed multiple myeloma.
    Ishida T; Kimura H; Ozaki S; Kubo K; Sunami K; Takezako N; Fujita H; Hayashi T; Kiguchi T; Ohashi K; Yamamoto S; Takamatsu H; Kosugi H; Ohta K; Sakai R; Handa H; Kondo S; Abe Y; Omoto E; Mitani K; Morita S; Murakami H; Shimizu K
    Ann Hematol; 2020 May; 99(5):1063-1072. PubMed ID: 32248251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
    Mateos MV; Oriol A; Martínez-López J; Gutiérrez N; Teruel AI; de Paz R; García-Laraña J; Bengoechea E; Martín A; Mediavilla JD; Palomera L; de Arriba F; González Y; Hernández JM; Sureda A; Bello JL; Bargay J; Peñalver FJ; Ribera JM; Martín-Mateos ML; García-Sanz R; Cibeira MT; Ramos ML; Vidriales MB; Paiva B; Montalbán MA; Lahuerta JJ; Bladé J; Miguel JF
    Lancet Oncol; 2010 Oct; 11(10):934-41. PubMed ID: 20739218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Daratumumab: A Review in Combination Therapy for Transplant-Ineligible Newly Diagnosed Multiple Myeloma.
    Syed YY
    Drugs; 2019 Mar; 79(4):447-454. PubMed ID: 30830601
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.
    Palumbo A; Bringhen S; Rossi D; Cavalli M; Larocca A; Ria R; Offidani M; Patriarca F; Nozzoli C; Guglielmelli T; Benevolo G; Callea V; Baldini L; Morabito F; Grasso M; Leonardi G; Rizzo M; Falcone AP; Gottardi D; Montefusco V; Musto P; Petrucci MT; Ciccone G; Boccadoro M
    J Clin Oncol; 2010 Dec; 28(34):5101-9. PubMed ID: 20940200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.